IHAM
MLYS icon

Integral Health Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Integral Health Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500,000
Closed -$13.5M – 108
2026
Q1 		$13.5M Buy
500,000
+250,000
+100% +$7.33M 0.65% 39
2025
Q4 		$9.07M Buy
+250,000
New +$10M 0.45% 60

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Integral Health Asset Management's MLYS Position: Q2 2026 in Review

Integral Health Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 40% in Q2 2026, selling an estimated $8.23M and leaving 450,000 shares worth $12.1M. The position accounts for 0.48% of the portfolio, ranked #54.

Integral Health Asset Management first reported a position in MLYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $56.9M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Integral Health Asset Management held 450,000 shares of Mineralys Therapeutics worth $12.1M as of Q2 2026.
  • Integral Health Asset Management sold 300,000 Mineralys Therapeutics shares in Q2 2026, an estimated $8.23M.
  • Mineralys Therapeutics made up 0.48% of Integral Health Asset Management's portfolio in Q2 2026, its #54 holding.
  • Integral Health Asset Management first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Integral Health Asset Management's Mineralys Therapeutics position peaked at $56.9M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.